GlycoMimetics Forges Ahead With Uproleselan In AML After Phase III Failure

The company said an NCI trial and a China study remain ongoing despite a Phase III study in relapsed/refractory disease failing, with an unusually long OS result in the control arm.

GlycoMimetics, Inc. is hoping that mining the data from its failed Phase III pivotal trial of uproleselan in acute myeloid leukemia (AML) can potentially yield some evidence of benefit in subgroup populations. Meanwhile, additional studies of the drug in other settings are ongoing.

The company said 6 May that the 388-patient Phase III pivotal study had not shown a statistically significant improvement in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

10 Jun 2025

• By Andrew McConaghie

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.